Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers

Tetsuya Aiba, Kazuya Ishida, Mariko Yoshinaga, Marie Okuno, Yukiya Hashimoto

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

To characterize the intestinal absorption of digoxin, its transcellular transport and drug interaction activity was investigated using Caco-2 cell monolayers. We examined digoxin transport in the presence and absence of ouabain to determine whether digoxin binding to Na+,K+-ATPase affects its transcellular digoxin transport, and evaluated its influx and efflux clearance by model-dependent pharmacokinetic analysis. Transcellular transport in the basal-to-apical direction was greater than that in the opposite direction. In addition, ouabain decreased the cellular accumulation of digoxin, but it did not alter its transcellular transport profile. The observations for transcellular transport and cellular accumulation in the presence of ouabain were used for the pharmacokinetic analysis, which showed that the efflux clearance of digoxin on the apical side of the monolayer was 15 times greater than that on the basal side. Apical-to-basal transport was increased by carvedilol and pimobendan, and these compounds suppressed the efflux clearance on the apical side and the influx clearance on the basal side. These findings indicate that the intestinal absorption of digoxin is primarily dominated by the efflux process on the luminal side of the intestine, and that carvedilol and pimobendan may vary the rate of intestinal digoxin absorption mainly by inhibiting its exsorptive transport.

Original languageEnglish
Pages (from-to)114-119
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 2005
Externally publishedYes

Fingerprint

Transcytosis
Caco-2 Cells
Digoxin
Drug Interactions
Pharmacokinetics
Intestinal Absorption
Ouabain
Intestines

Keywords

  • Caco-2 cell monolayer
  • Carvedilol
  • Digoxin
  • Intestinal absorption
  • Pimobendan

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers. / Aiba, Tetsuya; Ishida, Kazuya; Yoshinaga, Mariko; Okuno, Marie; Hashimoto, Yukiya.

In: Biological and Pharmaceutical Bulletin, Vol. 28, No. 1, 01.2005, p. 114-119.

Research output: Contribution to journalArticle

Aiba, Tetsuya ; Ishida, Kazuya ; Yoshinaga, Mariko ; Okuno, Marie ; Hashimoto, Yukiya. / Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers. In: Biological and Pharmaceutical Bulletin. 2005 ; Vol. 28, No. 1. pp. 114-119.
@article{1b08d842b8e948b9a81f9a387aa477f4,
title = "Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers",
abstract = "To characterize the intestinal absorption of digoxin, its transcellular transport and drug interaction activity was investigated using Caco-2 cell monolayers. We examined digoxin transport in the presence and absence of ouabain to determine whether digoxin binding to Na+,K+-ATPase affects its transcellular digoxin transport, and evaluated its influx and efflux clearance by model-dependent pharmacokinetic analysis. Transcellular transport in the basal-to-apical direction was greater than that in the opposite direction. In addition, ouabain decreased the cellular accumulation of digoxin, but it did not alter its transcellular transport profile. The observations for transcellular transport and cellular accumulation in the presence of ouabain were used for the pharmacokinetic analysis, which showed that the efflux clearance of digoxin on the apical side of the monolayer was 15 times greater than that on the basal side. Apical-to-basal transport was increased by carvedilol and pimobendan, and these compounds suppressed the efflux clearance on the apical side and the influx clearance on the basal side. These findings indicate that the intestinal absorption of digoxin is primarily dominated by the efflux process on the luminal side of the intestine, and that carvedilol and pimobendan may vary the rate of intestinal digoxin absorption mainly by inhibiting its exsorptive transport.",
keywords = "Caco-2 cell monolayer, Carvedilol, Digoxin, Intestinal absorption, Pimobendan",
author = "Tetsuya Aiba and Kazuya Ishida and Mariko Yoshinaga and Marie Okuno and Yukiya Hashimoto",
year = "2005",
month = "1",
doi = "10.1248/bpb.28.114",
language = "English",
volume = "28",
pages = "114--119",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers

AU - Aiba, Tetsuya

AU - Ishida, Kazuya

AU - Yoshinaga, Mariko

AU - Okuno, Marie

AU - Hashimoto, Yukiya

PY - 2005/1

Y1 - 2005/1

N2 - To characterize the intestinal absorption of digoxin, its transcellular transport and drug interaction activity was investigated using Caco-2 cell monolayers. We examined digoxin transport in the presence and absence of ouabain to determine whether digoxin binding to Na+,K+-ATPase affects its transcellular digoxin transport, and evaluated its influx and efflux clearance by model-dependent pharmacokinetic analysis. Transcellular transport in the basal-to-apical direction was greater than that in the opposite direction. In addition, ouabain decreased the cellular accumulation of digoxin, but it did not alter its transcellular transport profile. The observations for transcellular transport and cellular accumulation in the presence of ouabain were used for the pharmacokinetic analysis, which showed that the efflux clearance of digoxin on the apical side of the monolayer was 15 times greater than that on the basal side. Apical-to-basal transport was increased by carvedilol and pimobendan, and these compounds suppressed the efflux clearance on the apical side and the influx clearance on the basal side. These findings indicate that the intestinal absorption of digoxin is primarily dominated by the efflux process on the luminal side of the intestine, and that carvedilol and pimobendan may vary the rate of intestinal digoxin absorption mainly by inhibiting its exsorptive transport.

AB - To characterize the intestinal absorption of digoxin, its transcellular transport and drug interaction activity was investigated using Caco-2 cell monolayers. We examined digoxin transport in the presence and absence of ouabain to determine whether digoxin binding to Na+,K+-ATPase affects its transcellular digoxin transport, and evaluated its influx and efflux clearance by model-dependent pharmacokinetic analysis. Transcellular transport in the basal-to-apical direction was greater than that in the opposite direction. In addition, ouabain decreased the cellular accumulation of digoxin, but it did not alter its transcellular transport profile. The observations for transcellular transport and cellular accumulation in the presence of ouabain were used for the pharmacokinetic analysis, which showed that the efflux clearance of digoxin on the apical side of the monolayer was 15 times greater than that on the basal side. Apical-to-basal transport was increased by carvedilol and pimobendan, and these compounds suppressed the efflux clearance on the apical side and the influx clearance on the basal side. These findings indicate that the intestinal absorption of digoxin is primarily dominated by the efflux process on the luminal side of the intestine, and that carvedilol and pimobendan may vary the rate of intestinal digoxin absorption mainly by inhibiting its exsorptive transport.

KW - Caco-2 cell monolayer

KW - Carvedilol

KW - Digoxin

KW - Intestinal absorption

KW - Pimobendan

UR - http://www.scopus.com/inward/record.url?scp=18444414855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444414855&partnerID=8YFLogxK

U2 - 10.1248/bpb.28.114

DO - 10.1248/bpb.28.114

M3 - Article

C2 - 15635174

AN - SCOPUS:18444414855

VL - 28

SP - 114

EP - 119

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 1

ER -